The Pharma Letter2d
EC approves added use for J&J’s Lazcluze combo with Rybrevant for lung cancer
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
The Pharma Letter2d
J&J’s Spravato first approval as monotherapy for treatment-resistant depression
US healthcare giant Johnson & Johnson announced the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray as the first ...
Blackpool Gazette6d
Care home residents meet adorable alpacas
Staff and residents at Barchester’s Glenroyd care home in Blackpool were treated to a virtual tour of JandJ Alpacas, a family ...
Earnings call transcript: Johnson & Johnson Q3 2024 beats EPS forecast
Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02. The ...
MNI10d
HEALTHCARE: J&J Headline
of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to ...